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Abstract
Activation of innate immunity (natural killer cell/interferon-γ: NK cell/IFN-γ) has been shown to
play an important role in anti-viral and anti-tumor defenses as well as anti-fibrogenesis. However,
little is known about the regulation of innate immunity during chronic liver injury. Here, we
compared the functions of NK cells in early and advanced liver fibrosis induced by a 2-week or a
10 week-carbon tetrachloride (CCl4) challenge, respectively. Injection of poly I:C or IFN-γ
induced NK cell activation and NK cell killing of hepatic stellate cells (HSCs) in the 2-week CCl4
model. Such activation was diminished in the 10-week CCl4 model. Consistent with these
findings, the inhibitory effect of poly I:C and IFN-γ on liver fibrosis was markedly reduced in the
10-week vs. the 2-week CCl4 model. In vitro co-culture experiments demonstrated that 4-day
cultured (early-activated) HSCs induce NK cell activation via an NKG2D-retinoic acid-induced
early gene 1 (RAE1)-dependent mechanism. Such activation was reduced when co-cultured with
8-day cultured (intermediately-activated) HSCs due to the production of transforming growth
factor-β (TGF-β) by HSCs. Moreover, early-activated HSCs were sensitive, while intermediately-
activated HSCs were resistant to IFN-γ mediated inhibition of cell proliferation, likely due to
elevated expression of suppressor of cytokine signaling 1 (SOCS1). Disruption of the SOCS1 gene
restored the IFN-γ inhibition of cell proliferation in intermediately-activated HSCs. Production of
retinol metabolites by HSCs contributed to SOCS1 induction and subsequently inhibited IFN-γ
signaling and functioning, while production of TGF-β by HSCs inhibited NK cell function and
cytotoxicity against HSCs.
Conclusion—The anti-fibrogenic effects of NK cell/IFN-γ are suppressed during advanced liver
injury, which is likely due to the increased production of TGF-β and expression of SOCS1 in
intermediately-activated HSCs.
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Liver lymphocytes are enriched in natural killer (NK) cells, which play a crucial role in
innate immune responses against tumors and pathogenes.1, 2 Recent studies have
demonstrated that NK cells also play an important role in suppressing liver fibrosis via
killing activated hepatic stellate cells (HSCs) and producing interferon-γ (IFN-γ) in mice
and humans.3-5 IFN-γ not only directly induces HSC apoptosis and cell cycle arrest 6 but
also stimulates the cytotoxicity of NK cells against activated HSCs via increasing the
number of NK cells and upregulation of tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) on NK cells.4, 7 Recently, we have demonstrated that retinol metabolites
plays an important role in enhancing the sensitivity of activated HSCs to NK cell killing.8
HSCs store large amounts of vitamin A (retinol) in their cytoplasm. Upon activation, they
lose their retinol via either release or metabolism of retinol into retinoic acid, which has
been implicated in the pathogenesis of liver fibrogenesis.8-10 Retinoic acid is elevated in the
HSCs during activation and upregulates the expression of a variety of genes, including
retinoic acid-induced early gene 1 (RAE1), an NK cell activating ligand. RAE1 then
activates NK cells and increases the susceptibility of HSCs to NK cell killing.4, 8
Emerging evidence suggests that liver fibrosis can be reversed and prevented either via
inhibiting HSC activation and proliferation or inducing HSC apoptosis in various immune
cell and cytokines-dependent manners.2-7, 9, 10 Among these mechanisms, NK cells/IFN-γ
have been suggested to be one of the most potent negative regulators of liver fibrosis. In vivo
activation of NK cells by poly I:C or treatment with IFN-γ ameliorates liver fibrosis induced
by carbon tetrachloride (CCl4) or dimethylnitrosamine in rodents.4, 6, 11, 12 In addition,
clinical studies have shown that IFN-γ treatment attenuates liver fibrosis in some patients
with chronic viral hepatitis B (HBV) and HCV infection.13, 14 However, other clinical trials
reported that IFN-γ therapy had no beneficial effects in attenuating the severity of advanced
fibrosis and cirrhosis in patients with chronic HCV infection.15 The reasons for these
controversial reports are not clear. One of possible explanation may be due to the selection
of patients with different degrees of liver diseases. In the present study, we compared the
antifibrotic efficacy of NK cells/IFN-γ on early and advanced liver fibrosis in vivo and the
effects of NK cells/IFN-γ on the different stages of activated HSCs in vitro.
Materials and Methods
Animals
C57BL/6J mice and IFN-γ−/− mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). IFN-γ−/−SOCS1−/− mice were kindly provided by Dr. James Ihle, St. Jude
Children’s Research Hospital (Memphis, TN). All mice used in the present study were
housed in a specific pathogen–free facility and were cared for in accordance with National
Institutes of Health (NIH) guidelines. All animal experiments were approved by the
Institutional Animal Care and Use Committees of the NIAAA, NIH.
Liver fibrosis induction and co-treatment with CCl4 plus poly I:C or IFN-γ
Hepatic fibrosis in mice was induced experimentally by intraperitoneal injection (i.p) of
CCl4 as previously described.6 Mice were injected with CCl4 for 2 weeks or 8 weeks and
co-treated with or without poly I:C (2μg/g, 3 times a week, i.p) or IFN-γ (2000 IU/g, 7 times
per week, SC) for an additional 2 or 4 weeks. Control mice received CCl4 plus saline. For
acute poly I:C treatment, mice were injected (i.p) with poly I:C once.
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Statistical analysis
Data are expressed as means ± SEM. To compare values obtained from two or more groups,
the student t-test or one-way analysis of variance was performed. A value of P < 0.01 or
0.05 was considered significant.
Other methods
All other methods are described in the supporting documents.
Results
Poly I:C-mediated activation of NK cells is diminished in advanced liver fibrosis compared
with early stage of liver fibrosis
To investigate functions of NK cells on early stage (2-week CCl4) or advanced liver fibrosis
(10-week CCl4), mice were injected with CCl4 for 2 or 10 weeks without or with co-
treatment of poly I:C (for the final 2 weeks). In 2-week CCl4 group, serum IFN-γ levels
were significantly increased after poly I:C treatment, but such elevation was not observed in
10-week CCl4 (Fig. 1A). In addition, basal levels of serum IFN-γ from the 10-week CCl4
mice without poly I:C treatment were lower than those from 2-week CCl4 mice. Flow
cytometry analyses showed the basal levels of liver NK cell population and NKG2D
expression on these cells were significantly lower in 10-week CCl4 mice compared with
those in 2-week CCl4 mice (Fig. 1B). Interestingly, poly I:C treatment resulted in about 2-
fold induction of liver NK cell population and NKG2D expression in both 2-week and 10-
week CCl4 mice (Fig. 1B). Furthermore, poly I:C induction of several NK cell-associated
genes in the livers of 10-week CCl4 mice was diminished compared to those of 2-week CCl4
mice (Fig. 1C).
Cytotoxicity assay demonstrated that poly I:C treatment significantly increased cytotoxicity
of NK cells isolated from 2-week CCl4 mice against Yac-1 cells (NK sensitive target cells)
but not those of NK cells isolated from 10-week CCl4 mice (Fig. 1D). Cytotoxicity of spleen
NK cells against Yac-1 cells was also diminished in 10-week CCl4 vs 2-week CCl4 mice
(Supporting Fig. S1). In addition, NK cells isolated from poly I:C-treated or non-treated
mice of 10-week CCl4 mice showed significant reductions in killing of early-activated HSCs
(Fig. 1E) and IFN-γ production (Fig. 1F) compared to those of 2-week CCl4 mice.
IFN-γ-mediated activation of NK cells are diminished in advanced liver fibrosis compared
to early stage of liver fibrosis
Previously, it has been demonstrated that IFN-γ enhances the cytotoxicity of NK cells
against activated HSCs via increasing the number of NK cells and production of IFN-γ.4, 6, 7
Fig. 2A shows that the basal levels of liver NK cells and NKG2D expression were lower in
10-week CCl4 mice than those in 2-week CCl4 mice although IFN-γ treatment resulted in a
similar fold induction of these parameters in both groups. RT-PCR analyses showed IFN-γ
treatment markedly upregulated the expression of NKG2D, TRAIL, perforin and IFN-γ
genes in liver NK cells from 2-week CCl4 mice but not from 10-week CCl4 mice (Fig. 2B).
Cytotoxicity assay against Yac-1 cells showed IFN-γ treatment significantly increased
cytotoxicity of NK cells isolated from 2-week CCl4 mice but not those from 10-week CCl4
mice (Fig. 2C). In the case of spleen NK cells, cytotoxicity against Yac-1 cells was also
diminished in 10-week CCl4 mice compared to 2-week CCl4 mice (Supporting Fig. S2).
Additionally, NK cells isolated from IFN-γ-treated or non-treated mice of 10-week CCl4
mice had lower killing activity against activated HSCs compared to those of 2-week CCl4
mice (Fig. 2D).
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Poly I:C or IFN-γ treatment does not ameliorate advanced liver fibrosis
We and others have previously shown that poly I:C or IFN-γ treatment ameliorates early
liver fibrosis in mice.4, 6, 11, 12 Here we show that treatment with poly I:C inhibited liver
fibrosis induced by a 2-week CCl4 treatment but had no inhibitory effects on advanced liver
fibrosis induced by a 10-week CCl4 challenge (Figs. 3A-B). Moreover, poly I:C treatment
reduced expression of α-SMA and transforming growth factor-β1 (TGF-β1) in HSCs from
2-week CCl4 mice, while such inhibition was not observed in HSCs from 10-week CCl4
mice (Fig. 3C). HSCs from 10-week CCl4 mice had higher levels of α-SMA expression
compared with those from 2-week CCl4 mice, while expression of RAE1, an NK cell
activating ligand, was comparable in the HSCs from both groups (supporting Fig. S3A).
Next, we examined the effects of IFN-γ on advanced liver fibrosis induced by 10- or 12-
week CCl4 administration. Treatment with IFN-γ for 2 weeks inhibited liver fibrosis in 2-
week CCl4 group; however, IFN-γ treatment for the final 2 weeks or 4 weeks did not affect
10- or 12-week CCl4-induced liver fibrosis as determined by α-SMA staining and
hydroxyproline contents (Figs. 3D-E). After IFN-γ injection, serum IFN-γ levels increased
in all groups (Supporting Fig. S3B).
To understand the mechanism underlying the ineffectiveness of IFN-γ treatment on
advanced liver fibrosis, IFN-γ activation of STAT1 was investigated in isolated HSCs from
2-week, 8-week, or 12-week CCl4 mice. As illustrated in Fig. 3F, IFN-γ treatment inhibited
the expression of α-SMA and TGF-β1 in 2-week CCl4 mice but not in 10- or 12-week CCl4
mice. STAT1 was phosphorylated in isolated HSCs of the IFN-γ treated-2-week group, but
not in HSCs of the IFN-γ treated 10- or 12-week group. Finally, expression of SOCS1
protein, a negative regulator of STAT1,16 in HSCs was upregulated in 2-week CCl4 mice
after IFN-γ treatment. HSCs isolated from 10- or 12 week CCl4 mice had higher basal levels
of SOCS1 protein than those from 2-week CCl4 mice, which were not further upregulated
after IFN-γ treatment (Fig. 3F).
Early-activated D4 HSCs induce more NK cell activation than intermediately-activated D8
HSCs: Suppression by TGF-β1
To further understand the underlying mechanism of suppressed NK cell function observed in
the advanced liver fibrosis, day 4 (early-activated) or day 8 (intermediately activated)
cultured HSCs (D4 or D8 HSCs) were co-cultured with liver NK cells for 24 hours. After
co-culturing with HSCs, IFN-γ production by NK cells was significantly increased in co-
culturing with D4 HSCs or with D8 HSCs. Higher levels of IFN-γ were observed when co-
cultured with D4 HSCs than those with D8 HSCs (Fig. 4A). Co-culture studies of IFN-γ-
deficient cells suggest that the source of IFN-γ production is from NK cells (Fig. 4B).
Furthermore, incubation with NKG2D neutralizing antibody diminished IFN-γ production in
the co-culture experiments (Fig. 4C), suggesting that activated HSCs induce IFN-γ
production by NK cells via an NKG2D-dependent mechanism.
Expression of TGF-β protein was significantly higher in D8 HSCs compared with D4 HSCs
(Fig. 4D). Since TGF-β is a potent inhibitor for NK cells,7, 17 we hypothesized that TGF-β1
produced by co-cultured HSCs may inhibit IFN-γ production and cytotoxicity of NK cells.
As illustrated in Fig. 4E, incubation with TGF-β neutralizing antibody markedly enhanced
NK cell cytotoxicity against D8 HSCs as well as D4 HSCs (albeit to a lesser extent). In
addition, TGF-β antibody treatment increased IFN-γ production by NK cells when co-
cultured with D8 HSCs but did not affect IFN-γ production in co-culture experiment with
D4 HSCs (Fig. 4F). Furthermore, the addition of TGF-β1 ligand suppressed the cytotoxicity
of NK cells against D4 and D8 HSCs (Supporting Fig. S4).
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Intermediately-activated HSCs are less responsive to IFN-γ stimulation than early-
activated HSCs due to upregulation of SOCS1 expression
Although IFN-γ-mediated STAT1 activation has been well documented in HSCs,6, 11, 12, 18
the aforementioned experiments show that IFN-γ activation of STAT1 in HSCs from livers
with advanced liver fibrosis appears to be disrupted (Fig. 3F). To study the underlying
mechanisms responsible for the disruption, IFN-γ-mediated inhibitory cell proliferation and
activation of STAT1 were compared on D4 and D8 HSCs. As shown in Fig. 5A, IFN-γ
treatment suppressed cell proliferation of D4 HSCs, but not D8 HSCs. Western blotting
showed that IFN-γ induced STAT1 activation (phosphorylated STAT1) in D4 HSCs, but this
activation was markedly attenuated in D8 HSCs (Fig. 5B and Supporting Fig. S5A).
Immunocytochemical analyses confirmed that IFN-γ treatment induced STAT1 activation in
D4 HSCs, but not in D8 HSCs (Fig. 5C). Intriguingly, D8 HSCs expressed higher levels of
SOCS1 mRNA compared to D4 HSCs, although expression of IFN-γR1 and R2 were similar
in both types of cells (Fig. 5D). To determine whether induced SOCS1 protein is responsible
for the insensitivity of D8 HSCs to IFN-γ, IFN-γ−/−SOCS1−/− and IFN-γ−/−SOCS1+/+
HSCs were isolated and cultured for 8 days. SOCS1−/− mice are not embryonic lethal but
they die within 3 weeks after birth.19 Therefore, we used IFN-γ−/−SOCS1−/− mice that
survive well to isolate SOCS1−/− HSCs. Lack of SOCS1 protein and mRNA expression in
IFN-γ−/−SOCS1−/− HSCs was confirmed (Fig 5E and Supporting Fig. S5B). IFN-γ
activation of STAT1 and inhibition of HSC proliferation were restored in D8 IFN-
γ−/−SOCS1−/− HSCs (Figs. 5E-F).
Inhibition of retinol metabolism by 4-methyl pyrazole (4-MP) blocks SOCS1 induction
Retinol metabolites, in particular retinoic acid (RA), have been reported to induce SOCS3
mRNA expression in primary cultured astrocytes and C6 cells.20 Furthermore, HSCs
produce high levels of RA during activation.8 Thus, we hypothesized that induction of RA
may also contribute to SOCS1 induction in HSCs during activation. To test this hypothesis,
4-MP, a selective inhibitor of alcohol dehydrogenase (ADH) enzymes, was used to inhibit
retinol metabolism in HSCs. As illustrated in Fig. 6A, 4-MP treatment significantly reduced
metabolism of retinol into retinaldehydes (Ralds) and RAs. Induction of SOCS1 and SOCS3
mRNAs on HSCs was remarkably reduced in the 4-MP-treated group (Fig. 6B). Western
blotting showed that expression of SOCS1 protein was detected in vehicle-treated, but not in
4-MP-treated D8 HSCs (Fig. 6C). Finally, 4-MP treatment restored IFN-γ activation of
STAT1 (Fig. 6C) and IFN-γ inhibition of cell proliferation in D8 HSCs (Fig. 6D).
Retinol metabolites induce SOCS1 protein in HSCs
The above findings suggest that retinol metabolites may induce SOCS1 expression in HSCs.
To test this notion, the effects of various retinol metabolites (retinaldehydes and retinoic
acids) on SOCS1 expression in HSCs were investigated. Expression of SOCS1 gene was
markedly induced in HSCs treated with 9-cis Rald and 9-cis RA, whereas all trans Rald and
all trans RA treatments only resulted in slight induction (Fig. 7A). To investigate which
types of retinoic acid receptors (RARs) and retinoid X receptors (RXRs) were involved in
SOCS1 induction, HSCs were treated with RAR agonist (CD437) and a RXR agonist
(methoprene acid, MA). After treatment, only CD437 RAR agonist induced SOCS1
expression in D2 HSCs (Fig. 7B). Additionally, the effects of 9-cis Rald, 9-cis RA and
CD437 on IFN-γ signaling in HSCs were explored. As illustrated in Figs. 7C-D, IFN-γ
treatment induced pSTAT1 activation and SOCS1 expression in vehicle-treated D4 HSCs.
Such STAT1 activation was attenuated in 9-cis Rald, 9-cis RA and CD437-pretreated HSCs
compared to control (vehicle) group. Furthermore, treatment with 9-cis Rald and CD437 but
not 9-cis-RA upregulated SOCS1 protein in HSCs compared to vehicle group.
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Discussion
Numerous studies have shown that treatment with poly I:C or IFN-γ, at the onset or early
stages, prevents liver fibrosis in rodents via enhanced activation of NK cells/IFN-γ against
HSCs.4-6, 11, 12 In this report, we demonstrated that the antifibrotic effects of poly I:C and
IFN-γ were diminished in advanced liver fibrosis induced by a 10-week CCl4 treatment, and
that retinol metabolites play an important role in inhibiting the anti-fibrotic effects of NK
cell and IFN-γ via induction of TGF-β1 and SOCS1 protein, respectively. In addition, retinol
metabolites may also enhance NK cell function via induction of NK cell activating ligand
expression on HSCs. We have summarized our findings into a proposed model as shown in
Fig. 8.
The antifibrotic effects of NK cells and IFN-γ have been previously documented in various
models; however, the majority of these studies were conducted on the model of early stage
of liver fibrosis.4-6, 11, 12, 18 Here we provided multiple lines of evidence suggesting that
the anti-fibrotic functions of NK cells/IFN-γ are suppressed in advanced liver fibrosis. First,
poly I:C and IFN-γ treatment did not ameliorate advanced liver fibrosis induced by a 10-
week CCl4 treatment; Second, serum levels of IFN-γ were not increased by poly I:C
treatment in the model of advanced liver fibrosis (Fig. 1A); Third, liver NK cells from 10-
week CCl4 challenged mice display lower cytotoxicity against both Yac-1 cells and HSCs
than those from 2-week CCl4 mice (Figs. 1-3), suggesting NK cell functions are impaired in
advanced liver fibrosis; Fourth, the number of activated NK cells and expression of NK
cells-associated genes were lower in advanced liver fibrosis vs. early stage of liver fibrosis
(Figs. 1 and 2). Finally, IFN-γ activation of STAT1, a major mediator of IFN-γ signaling,
was suppressed in HSCs from the advanced fibrotic liver (Fig. 3F) or in intermediately-
activated D8 HSCs (Fig. 5B) despite expression of high levels of IFN-γRs on these HSCs
(Supporting Fig. S6 and Fig. 5D). These data suggest that IFN-γ treatment is likely effective
in treating early stages of liver fibrosis but not advanced liver fibrosis, and lack of effects of
IFN-γ therapy on liver fibrosis observed in clinical trials may be due to the selection of
patients with advanced liver fibrosis.15
The next question is what are the mechanisms underlying the decreased anti-fibrotic effects
of NK cells/IFN-γ in advanced liver fibrosis. The studies from current paper suggest that
TGF-β and retinoic acid contribute to inhibition of NK cell functions and IFN-γ signaling
pathways, respectively, in advanced liver fibrosis. Recently, it has been suggested that the
enhanced production of IFN-γ by NK cells could be derived from interaction with activating
HSCs in liver diseases.1, 2, 4-8 In the current study, we provide several lines of evidence
suggesting that early-activated HSCs express high levels of RAE1, an NK cell activating
ligand, which can induce NK cell activation and production of IFN-γ, while intermediately-
activated HSCs may inhibit NK cell activity via producing high levels of TGF-β. First, IFN-
γ production by NK cells was significantly enhanced when co-cultured with early-activated
D4 HSCs, yet compared to D4 HSCs, IFN-γ production was lower when co-cultured with
intermediately-activated D8 HSCs (Fig. 4). Second, Western blotting and RT-PCR analyses
showed that TGF-β1 mRNA and protein expression were highly induced in HSCs from
advanced liver fibrosis (Figs. 3C-F) and intermediately-activated D8 HSCs (Fig. 4D). Third,
blocking TGF-β with a neutralizing antibody increased NK cell killing and restored IFN-γ
production of NK cells (Fig. 4E,F), whereas treatment with TGF-β decreased NK cell
cytotoxicity (Supporting Fig. S4). Finally, TGF-β is known to inhibit NK cell-mediated
cytotoxicity and cytokine production. 7, 17, 21 Taken together, TGF-β likely plays an
important role in inhibiting the anti-fibrotic effect of NK cells and resistance of
intermediately-activated HSCs to NK cell killing is likely mediated by the overproduction of
TGF-β. In addition to HSCs that are known to be one of the major sources for TGF-β
production in the fibrotic liver and its production is proportional to the grade of liver
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fibrosis,9, 10 Kupffer cells also play an important role in producing TGF-β during liver
fibrogenesis.22 Future studies are required to determine whether Kupffer cells can also
negatively regulate NK cell functions via production of TGF-β in the advanced liver
fibrosis.
In addition to resistant to NK cell killing, HSCs isolated from advanced fibrotic liver or
intermediately-activated D8 HSCs are also less responsive to IFN-γ stimulation (Fig. 3F and
Supporting Figs. S3 and S6). The reduced responsiveness of these cells to IFN-γ stimulation
is likely due to the increased expression of SOCS1 (Fig. 3F and Figs. 5B-D) as SOCS1 is
known to be a key mediator in suppressing IFN-γ signaling.23 This conclusion was
supported by the fact that IFN-γ inhibition of cell proliferation and activation of STAT1
were restored in D8 cultured IFN-γ−/−SOCS1−/− HSC compared to D8 IFN-γ−/−SOCS1+/+
HSCs (Figs. 5E-F). Further experiments suggest that upregulation of SOCS1 in D8 HSCs is
due to RA production during HSC activation.
Quiescent HSCs store approximately 80% retinols of the body which are released or
metabolized into Ralds by alcohol dehydrogenase (ADH) and subsequently RA by
retinaldehyde dehydrogenases (Raldh) during HCS activation.8, 24, 25 An increase of RA
and a decrease of retinol content have been reported in CCl4 and thioacetamide-induced
fibrotic livers of rats, and in cultured HSCs.8, 26 In the current paper, we demonstrated that
inhibition of retinol metabolism by 4-MP reduced expression of SOCS1 and subsequently
increased the IFN-γ activation of STAT1 signaling in HSCs (Fig. 6), suggesting a role of
retinol metabolites in the induction of SOCS1 in HSCs. The fact that treatment with 9-cis
Rald, 9-cis RA or CD437 (an agonist of RAR-β/γ)8, 25, 27 induced SOCS1 expression and
attenuated STAT1 phosphorylation of IFN-γ in HSCs (Fig. 7) clearly indicates that retinol
metabolites inhibit IFN-γ signaling via induction of SOCS1 in HSCs.
In conclusion, the current study demonstrated that intermediately-activated HSCs displayed
resistance to IFN-γ stimulation and NK cell killing via a RA-mediated SOCS1 and TGF-β
dependent manner despite the enhanced expression of RAE1 (Fig. 8). These data potentially
provide insight into the mechanisms underlying the resistance to NK cells/IFN-γ therapy in
patients with advanced liver fibrosis. Therefore, retinol metabolites/SOCS1/TGF-β could be
a potential therapeutic target for improving the efficacy of IFN-γ treatment and NK cell
therapy in treating liver fibrosis.
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Fig. 1.
Poly I:C activation of liver NK cells is suppressed in 10-week CCl4 model compared with 2-
week CCl4 model. Two-week or 10-week CCl4-treated mice were co-injected with poly I:C
for the last 2 weeks. (A) Serum levels of IFN-γ. (B-C) Liver mononuclear cells (MNCs) and
NK cells were isolated and subject to FACS analyses (B) and RT-PCR analyses (C). (D-E)
Liver NK cells were used as effector cells for cytotoxicity assay against Yac-1 cells (D) or
cultured day 4 HSCs (D4 HSCs) (E). (F) Liver NK cells from 2-week or 10-week CCl4-
treated mouse with or without poly I:C were cultured in serum free medium for 16 h for
measurement of IFN-γ levels. *P<0.05, **P<0.01.
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Fig. 2.
IFN-γ activation of liver NK cells is diminished in 10-week CCl4 model compared with 2-
week CCl4 model. Two-week or 10-week CCl4-treated mice were injected with IFN-γ for
the last 2 weeks. MNCs and NK cells were isolated and subjected to FACS analyses (A) and
RT-PCR analyses (B). Liver NK cells were used as effector cells for cytotoxicity assay
against Yac-1 cells (C) and D4 HSCs (D). *P<0.05, **P<0.01.
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Fig. 3.
Poly I:C or IFN-γ treatments inhibits liver fibrosis induced by 2-week CCl4 but not by 10-
week CCl4 treatment. Two-week or 10-week CCl4-treated mice were co-injected with poly
I:C for the last 2 weeks. (A-B) Liver tissues were collected for immunohistochemistry
analyses with anti-α-SMA antibody (A), measurement of hepatic hydroxyproline content
(B). (C) HSCs were isolated from the mouse liver and then subject to Western blotting. (D-
E) Mice were injected with CCl4 plus IFN-γ for 2 weeks, or with CCl4 for 8 weeks and then
co-treatment of CCl4 plus IFN-γ for an additional 2 or 4 weeks. Liver tissues were
subsequently collected and subject to immunohistochemistry analyses with anti-α-SMA
antibody (D) and measurement of hepatic hydroxyproline content (E). (F) Protein extracts
from HSCs were subject to Western blotting. *P<0.05.
Jeong et al. Page 12
Hepatology. Author manuscript; available in PMC 2012 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Early-activated D4 HSCs induce more NK cell activation (IFN-γ production) than
intermediately-activated D8 HSCs: suppression by TGF-β. (A-C) IFN-γ levels from the
supernatant of co-culture of liver NK cells and HSCs for 24 h. (A) Co-culture of NK with
D0-D8 HSCs. (B) Co-culture of IFN-γ+/+ or IFN-γ−/− NK cells with IFN-γ+/+ or IFN-γ−/−
D4 HSCs. (C) Co-culture of D4 HSCs with NK cells in the presence of anti-NKG2D
antibody or IgG control. (D) Western blotting of cultured HSCs. (E) Activated liver NK
cells from poly I:C-treated mice were used as effector cells in cytotoxicity assay against D0-
D8 HSCs in the presence of anti-TGF-β antibody or IgG controls. (F) D8 HSCs were
incubated with liver NK cells with or without anti-TGF-β antibody for 24 h. IFN-γ level in
the supernatant was measured. *P<0.05, **P<0.01 in comparison with corresponding
groups, &P<0.05 in comparison with D4 HSC.
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Fig. 5.
D8 HSCs are resistant to IFN-γ stimulation due to induction of SOCS1. HSCs were cultured
for 4 days (D4 HSCs) or 8 days (D8 HSCs). (A) D4 and D8 HSCs were treated with IFN-γ
and [3H] thymidine uptake was determined. D4 and D8 HSCs was treated with IFN-γ for 30
min, followed by Western blot analysis (B) or immunocytochemistry analyses (C) with anti-
pSTAT1, STAT1 or SOCS1 antibodies. In panel C, the black arrows indicate positive
pSTAT1 staining in the nuclei. Open arrows indicate negative staining. (D) RT-PCR
analyses of cultured HSCs. (E) Western blot analyses of D8 IFN-γ−/−SOCS1+/+ and IFN-
γ−/−SOCS1−/− HSCs treated with IFN-γ for 30 min. (F) [3H] thymidine uptake analyses of
D8 IFN-γ−/−SOCS1+/+ and IFN-γ−/−SOCS1−/− HSCs treated with IFN-γ. **P<0.01
compared with corresponding groups.
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Fig. 6.
Inhibition of retinol metabolism by 4-MP blocks SOCS1 induction in intermediately-
activated HSCs. (A) Intracellular concentrations of retinol and retinol metabolites from
cultured HSCs treated with 4-MP. (B) RT-PCR analyses of cultured HSCs treated with 4-
MP. (C) Western blot analyses of HSCs treated with 4 MP and/or IFN-γ. (D) HSCs were
cultured with or without 4MP for 8 days, treated with IFN-γ and then [3H] thymidine uptake
was determined. *P<0.05, **P<0.01 compared with corresponding vehicle-treated groups.
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Fig. 7.
Retinol metabolites induce SOCS1 gene expression in HSCs, rendering HSC resistant to
IFN-γ treatment. (A-B) RT-PCR analyses of SOCS1 mRNA expression from HSCs treated
with retinol metabolites, RAR agonist CD437 or RXR agonist MA for 2 days. (C) HSCs
were cultured with various retinol metabolits for 4 days and then cultured in serum-free
medium for an additional 6 h, followed by treatment with IFN-γ for 30 min. Cell extracts
were then prepared for Western blotting. (D) The densities of bands in panel C were
quantified. *P<0.05, **P<0.01.
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Fig. 8.
A double edged sword role of retinol metabolites in HSCs against NK cell activation.
During HSC activation, retinols are metabolized into Rald or RA, which affect the
interaction of NK and HSCs in 2 ways. (1) RA induces expression of NK cell activating
ligand RAE1, which then activates NK cells through interaction with NKG2D. Activated
NK cells can directly kill early-activated HSCs via releasing TRAIL or inhibit HSCs via
releasing IFN-γ. IFN-γ induces cell cycle arrest and apoptosis of HSCs via activation of
STAT1. (2) Retinoids (Rald and RA) can inhibit IFN-γ-mediated activation of STAT1 via
induction of SOCS1, a key negative inhibitor of IFN-γ signaling, in intermediately-activated
HSCs. Also, RA can activate latent TGF-β, which then inhibits NK cell activity. Therefore,
retinol metabolism during HSC activation can promote NK cell activation via induction of
RAE1, but can also downregulate NK cell activity via induction of TGF-β that inhibits NK
cell activity, or induction of SOCS1 that inhibits IFN-γ signaling.
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